Navigation Links
ChemBridge Research Laboratories, Inc. (CRL) has Established an Industry Record and Benchmark in Hit-to-Lead Libraries Turn-around Time

SAN DIEGO, Aug. 7 /PRNewswire/ -- ChemBridge Research Laboratories, Inc. (CRL) announced today that it has established an industry record in turn-around time for hit-to-lead follow-up libraries. Such ultra-fast hit-to-lead libraries are now produced in CRL's San Diego facilities in a matter of three to six days which enables critical acceleration of our clients' medicinal chemistry projects and sets a new industry benchmark. This state-of-the-art high-throughput chemistry technology was developed at CRL over the last seven years and refined in collaborations with Pfizer, Merck, AstraZeneca and others.

CRL's ultra-fast library production process is optimized at every step and includes: on-the-fly building block validation and protocol adjustment; one to three parallel synthesis steps across a very broad reaction range; high-throughput HPLC purification and LC/MS analysis; data processing; and robotic reformatting to ready-to-be-shipped custom plates/vials. The expertise, problem solving ability, and versatility of synthetic skills of CRL's chemists (the majority of whom are PhD's) also allow for rapid development of new parallel synthetic protocols and multi-step synthesis of intermediates and templates on-the-fly for the most challenging research-intensive hit-to-lead libraries.

"We are very pleased that our CRL chemists have been able to achieve speed and efficiency in hit-to-lead library production which even a year ago was not considered possible," said Eugene Vaisberg, Chairman and CEO of ChemBridge Corporation and CRL. "Their ability to produce and deliver high quality hit-to-lead libraries in less than a week continues the ChemBridge tradition of setting a gold standard in discovery chemistry outsourcing. It also offers a substantial competitive advantage for our clients allowing their precious medicinal chemistry resources to focus on their core expertise and to improve their hit-to-drug candidate success rate and timelines. This is of foremost importance now when research efficiency and productivity becomes the 'name of the game' for the pharmaceutical and biotech industry."

About ChemBridge Research Laboratories, Inc. (CRL)

ChemBridge Research Laboratories, Inc. (CRL),, is a San Diego based discovery chemistry CRO, which provides chemistry solutions for early stages of small molecule drug discovery. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL has now become a center of excellence in high-throughput medicinal chemistry with a particular focus on ultra-fast hit-to-lead libraries. CRL's world-class research team has exceeded expectations in all its collaborations, including multi-year alliances with Pfizer, Merck, AstraZeneca and other major pharmaceutical and biotech companies.

About ChemBridge Corporation

ChemBridge Corporation,, is a leading global discovery chemistry CRO and screening compound library provider with an impeccable 15 year track record of quality and deliverability. ChemBridge is a San Diego based company which operates a state-of-the-art offshore discovery chemistry research site in Moscow, Russia. ChemBridge's CRO business includes multi-year strategic alliances with major pharmaceutical companies such as Pfizer, Merck, and AstraZeneca, as well as smaller research collaborations with mid-size pharmaceutical and biotech companies. Over 500 pharmaceutical and biotech companies and universities worldwide have also taken advantage of ChemBridge's portfolio of advanced discovery chemistry off-the-self products, including its library of 700,000 diverse drug-like small molecule screening compounds and 10,000 building blocks.

SOURCE ChemBridge Research Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers report periodontal disease independently predicts new onset diabetes
2. Scripps research team unravels new cellular repair mechanism
3. Researchers Find Genes That Influence West Nile Virus
4. New Research From Best Practices: Pharmaceutical New Product Planning - Structure and Activities to Drive Growth and Profitability
5. UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research
6. Researchers unveil vital key to cancer
7. Researchers find differences in swallowing mechanism of Rett syndrome patients
8. Dartmouth researchers say too many children see extreme violence in movies
9. LegalView Brain Injury Site Reports Department of Veteran Affairs Request for Research on TBI and Soldiers
10. BCBSA: Time Is Right for Comparative Effectiveness Research Institute
11. Penn researchers find a new role for a Foxy Old Gene
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released a ... Mesothelioma has just posted the findings on the website. Click here to read ... of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College ... Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD ... colleges, as only one of twelve colleges and universities in the state of California ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology: